Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.
The company's technology involves the encapsulation, at room temperature, of active ingredients in micro- and nano-sized glass (silica) matrices as well as nanospheres utilizing a chemical process called sol-gel.
A drug delivery company developing enhanced and improved therapeutic medicines in several fields. Solubest is using advanced polymer formulations to prepare nanotransporters for drugs having delivery or compliance insufficiencies.
Sphere is commercializing picodroplet technology from Cambridge University that can perform thousands of simultaneous reactions on single cells and molecules contained within aqueous droplets, fractions of a millimeter in size. This platform enables diverse applications including: miniaturized profiling of drug candidates, generation of new biocatalysts and identification of novel algal strains.
SurModics® Synthetic ECM is a synthetic, stable, and scalable cell culture platform that provides an in vivo-like cell culture environment with its biomimetic extracellular matrix structure and surface. The technology produces results for cell research and cell-related applications. The nanofibrillar matrix utilizes Ultra-Web™ technology.
T2 Biosystems is creating a new generation of lab-quality diagnostic tools. Its technology is based on superparamagnetic nanoparticles. NanoDx particles have a superparamagnetic metal core surrounded by a polymer layer decorated by multiple analyte-specific binding agents. This nanoparticle platform can be used with a variety of binding agents such as antibodies, nucleic acids and small molecules.
The company specializes in the development, production, distribution and servicing of enabling solutions for the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Nanotechnology applications include a nanopipetting system.
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
The company has leveraged its experience with magnetic nanomaterials and magnetic field energy to make antibodies tumoricidal and more therapeutically selective, without the side effects of conventional therapies.
Developed and manufactures a novel, biomaterial which utilizes hydrogel nanoparticles which aggregate to form a material of varying strength and elasticity which has extensive medical application including wound management and burn care, tissue regeneration and drug delivery devices.
Vascular Magnetics, Inc. is magnetically targeting drug-loaded biodegradable nanoparticles to develop Vascular Magnetic Intervention (VMI), a novel therapy for peripheral artery disease (PAD). PAD is a common chronic condition characterized by obstruction (stenosis) of the arteries in the legs.
The company is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.
VisiGen Biotechnologies, Inc. is developing a revolutionary approach for DNA sequencing that will enable rapid, inexpensive whole genome sequencing. The VisiGen® sequencing system will become an enabling platform technology for single-molecule genetic analysis.
Offers new culture and exposure systems for in vitro studies of gases or complex mixtures. The VITROCELL modules offer new possibilities for the characterization of the effects of airborne substances such as gases nanoparticles and complex mixtures.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and commercialization of next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries.
WaveSense develops, manufactures, and markets breakthrough analytical nanotechnologies for use in cellular and molecular assay markets. The company's patented and hierarchy technology is called Xenographic Retention Chromatography (XRC) - branded as EpiSep, which is a lateral flow separations platform that provides rapid, advanced detection and characterization of live cells, proteins, and/or genes. Researchers can then harvest the targets for interrogation purposes within their desired application.